Abbott's Zemplar Capsules Approved for Earlier Treatment of SHPT

The FDA has approved Abbott Laboratories' Zemplar capsules, an oral, activated vitamin D therapy for prevention and treatment of secondary hyperparathyroidism (SHPT).

Zemplar (paricalcitol) capsules are indicated for the prevention and treatment of SHPT in Stages III and IV chronic kidney disease patients, before the need for dialysis or transplantation. Zemplar capsules are a new, oral formulation of Zemplar injection, which was introduced in 1998.